138 related articles for article (PubMed ID: 23176008)
1. Prevention of bone metastases and management of bone health in early breast cancer.
Gnant M; Hadji P
Breast Cancer Res; 2010; 12(6):216. PubMed ID: 21172067
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence.
Santini D; Stumbo L; Spoto C; D'Onofrio L; Pantano F; Iuliani M; Fioramonti M; Zoccoli A; Ribelli G; Virzì V; Vincenzi B; Tonini G
Breast Cancer Res; 2015 Sep; 17(1):121. PubMed ID: 26328589
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?
Casimiro S; Ferreira AR; Mansinho A; Alho I; Costa L
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27618899
[TBL] [Abstract][Full Text] [Related]
4. NCCN Task Force Report: Bone Health in Cancer Care.
Gralow JR; Biermann JS; Farooki A; Fornier MN; Gagel RF; Kumar RN; Shapiro CL; Shields A; Smith MR; Srinivas S; Van Poznak CH
J Natl Compr Canc Netw; 2009 Jun; 7 Suppl 3(Suppl 3):S1-32; quiz S33-5. PubMed ID: 19555589
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Clinical Literature Review of Managing Bone Metastases in Breast Cancer: Focus on Pain and Skeletal-Related Events.
Hamash K; Walker SL
Clin J Oncol Nurs; 2023 Nov; 27(6):615-628. PubMed ID: 38009875
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.
Liu Y; Du C; Zhang Y; Zhao S; Zhao L; Li P; Hu F; Zhu L; Liu Y; Pang D; Zhao Y
BMJ Open; 2015 Apr; 5(4):e007215. PubMed ID: 25900461
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates: are they standard of care for the treatment of breast cancer?
Pritchard KI
Br J Cancer; 2007 Jun; 96(12):1781-2. PubMed ID: 17565339
[No Abstract] [Full Text] [Related]
8. Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!
Azim HA; Kamal NS; Malak RA
J Thorac Dis; 2013 Jun; 5 Suppl 1(Suppl 1):S27-35. PubMed ID: 23819025
[TBL] [Abstract][Full Text] [Related]
9. [Whole-cycle management norms of bone health in breast cancer].
Breast Cancer Expert Committee of National Caner Quality Control Center
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(2):107-124. PubMed ID: 38186132
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
Freedman OC; Amir E; Clemons MJ
Crit Rev Oncol Hematol; 2009 Oct; 72(1):56-64. PubMed ID: 19307138
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
Li J; Rugo HS
Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
[TBL] [Abstract][Full Text] [Related]
12. Bone-modifying agents as adjuvant therapy for early-stage breast cancer.
Figueroa-Magalhães MC; Miller RS
Oncology (Williston Park); 2012 Oct; 26(10):955-62. PubMed ID: 23176008
[TBL] [Abstract][Full Text] [Related]
13. Denosumab and the current status of bone-modifying drugs in breast cancer.
Lee BL; Higgins MJ; Goss PE
Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
[TBL] [Abstract][Full Text] [Related]
14. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
15. [The role of bisphosphonates of adjuvant therapy in breast cancer].
Gálvez-Muñoz E; Rodríguez-Lescure Á
Med Clin (Barc); 2010 Jun; 135(2):70-4. PubMed ID: 20022069
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
